GlassScriptPhysician profile
John F Wiedner
NPI 1639151244
$655.55
in general payments reported to CMS, 2019-2025
14 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.09 · 2020: $39.39 · 2021: $63.88 · 2022: $49.93 · 2023: $95.94 · 2024: $51.43 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $300.13 | 2024-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $82.30 | 2019-2022 | |
| Lilly USA, LLC | $53.17 | 2021-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $32.67 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $30.93 | 2023 | Shingrix, Arexvy |
| Pfizer INC. | $29.39 | 2022-2024 | |
| Biogen, INC. | $18.62 | 2023 | Spinraza |
| Abbott Laboratories | $17.35 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.82 | 2025 | Zoryve |
| Avion Pharmaceuticals | $16.75 | 2023 | Balcoltra |
| Insulet Corporation | $15.44 | 2021 | |
| Eisai INC. | $14.91 | 2021 | |
| Esperion Therapeutics, INC. | $14.29 | 2020 | |
| Amarin Pharma, INC. | $12.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wiedner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.